Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype;Retrospektywna ocena tolerancji leczenia lekami przeciwdepresyjnymi u pacjentów z rozpoznaniem depresji, z różnym genotypem CYP2D6

Psychiatria Polska

Volumn 37, Issue 3, 2003, Pages 433-444

  Grzesiak, Magdalena ^a   Beszłej, Aleksander ^a   Lebioda, Arleta ^a   Jonkisz, Anna ^a   Dobosz, Tadeusz ^a   Kiejna, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Antidepressants; CYP2D6 genotype; Side effects

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; CYTOCHROME P450 2D6;

ADULT; AGED; ALLELE; ARTICLE; BIOTRANSFORMATION; CATALYSIS; CAUCASIAN; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; GENETIC ANALYSIS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OXIDATION; PSYCHIATRIC DIAGNOSIS; RETROSPECTIVE STUDY; SALIVA LEVEL; SIDE EFFECT;

ADULT; AGED; ALLELES; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 0041522354     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Blardi P. Farmacogenetica: Farmacokinetica ed implicazioni cliniche. Receti Prog. Med. 1997; 88: 46-55.
2. Brosen K. Isozyme specific drug oxidation: genetic polymorphism and drug-drug interactions. Nord. J. Psychiatry 1993; supl. 30: 21-26.
3. Gram LF, Brosen K. Genetic polymorphism in drug oxidation: implication for the clinical use of tricyclic antidepressants. W: Witmer CM, red. Genetic polymorphism of drug metabolism in humans. Biological active intermediates. New York: Plenum Press; 1990, s. 623-627.
4. Dahl M.-L, Bertilsson L, Ingelman-Sundberg M, Johansson I, Lundovist E, Sjoqvist F. Molecular basis of drug oxidation polymorphism. Nord. J. Psychiatry 1993; supl 30, 27-31.
5. Gaedigk A, Gotschall R, Forbes N, Simon S, Kearnes G, Leeder S. Optimization of cytochrome P450 2D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allelefrequency data. Pharmacogen. 1999; 9: 669-682.
6. Murphy MP, Meaman M, Clark LS, Cayouette M, Benson L, Morris D, Polli J. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of the phase III clinical trial. Pharmacogen. 2000; 10: 583-590.
7. Sachse Ch, Brockmoller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasians population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 1997; 60: 284-295.
8. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin. Pharmacokinet. 1995; 3: 192-209
9. Beszłej JA, Kiejna A. Znaczenie dla psychiatrii badania genetycznego polimorfizmu utleniania leków. Psychiatr. Pol 1995; 29, 1: 45-56.
10. Dalen P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-hydroxilation of nortriptyline in white persons with 0,1,2,3 and 13 functional CYP2D6. Clin. Pharmacol. Ther. 1998; 63: 444-452.
11. Dalen P, Dahl ML, Eichelbaum M, Bertilsson L, Wilkinson GR. Disposition of debrisoquine in Caucasians different CYP2D6-genotypes including those with multiple genes. Pharmacogen. 1999; 9: 697-706.
12. Haffen E, Vandel P, Broly F, Vandel S, Sechter D, Bizouard P, Bechtel PR. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype. Pharmacopsychiatry 1999; 32: 232-234.
13. Haffen E, Vandel P, Paintaud G, Broly F, Vandel S, Bonin B, Bizouard P, Sechter D, Bechtel PR. Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences? Eur. J. Clin. Pharmacol. 2000; 55: 877-879.
14. Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr. Scand. 1997; 96, supl. 391: 14-21.
15. Chen S, Chou W-H, Blouin R, Mao Z, Humphries L, Meek C, Neil J, Martin W, Hays L, Wedlund P. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol. Ther. 1996; 60: 522-534.
16. Coutts RT. Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. J. Psychiatr. Neurosci. 1994; 1: 30-34.
17. deLeon J, Barnhill J, Rogers T, Boyle J, Chou W-H, Wedlund PJ. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am. J. Psychiatry 1998; 155: 1278-1280.
18. Llerena A, Herraiz AG, Cobaleda J, Johansson I, Dahl M-L. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin. Pharmacol. Ther. 1993; 54: 606-611.
19. Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin. Pharmacokinet. 1991; 20: 447-466.
20. Radziwoń-Zaleska M, Matsumoto H, Skalski M, Kunicki P. Terapia monitorowana depresji. Farmakoter. Psychiatr. Neurol. 1995; 2-3: 42-53.
21. Walsch P, Metzger D, Higuchi R. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechn. 1991; 10: 506-513.
22. Radziwoń-Zaleska M, Matsumoto H, Skalski M, Androsiuk W, Dziklińska A, Kunicki PK. Therapeutic drug monitoring in depression. Pol. J. Pharmacol. 2000; 255-266.
23. Balant-Gorgia AE, Balant LP, Garrone G. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Ther. Drug Monit. 1989; 11: 415-420.
24. Chou WH, Yan FX, deLeon J, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, Teiling C, Wedlund PJ. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J. Clin. Psychopharmacol. 2000; 20: 246-251.
25. Topic E, Stefanovic M, Ivanisevic AM, Blazinic F, Culav J, Skocilic Z. CYP2D6 genotyping in patients on psychoactive drug therapy. Clin. Chem. Lab. Med. 2000; 38: 921-927.
26. Preskorn SH. Tricyclic antidepressants: the whys and hows of therapeutic drug monitoring. J. Clin. Psychiatry 1989; 50, supl. 7: 32-42.
27. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur. J. Clin. Pharmacol. 1997; 51: 395-398.
28. Terao T, Ohmori O, Shinkai T. A puzzling case of seizure and visual hallucinations during clomipramine treatment with high dose but causing a low serum concentration. Acta Psychiatr. Scand. 1999; 99: 388-392.
29. Miksys S, Rao Y, Sellers EM, Mendis D, Tyndale RF. Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica 2000; 30: 547-564.
30. Voirol P, Jonzier-Pery M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW, Kosel M, Eap CB, Baumann P. Cytochrome P-450 activietes in human and brain microsomes. Brain Res. 2000; 855: 235-243.
31. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibition. Pharmacol. Ther. 2000; 1: 11-28.
32. Leo RJ. Movement disorders associated with the selective serotonin reuptake inhibitors. J. Clin. Psychiatry 1996; 57: 449-466.
33. Linder MW, Prough RA, Valdes R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem. 1997; 2: 254-266.
34. Kapitany T, Meszaros K, Aschauer HN, Lenzinger E, Schindler SD, Barnas Ch, Fuchs K, Sieghard W, Kasper S. CYP2D6 genotypes and tardive dyskineza in schizophrenia. Homeostasis in Health and Disease. C.I.N.P. Regional Conference Vienna 1995, 36, supl. 1, czȩść 2, s. 71.